B Ahrén, G Pacini, JE Foley, A Schweizer - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—In subjects completing 52 weeks with participation in all meal tests
(n = 57), HbA 1c (A1C) decreased in the vildagliptin/metformin group (VM group,
n = 31) but increased in the placebo/metformin group (PM group, n = 26; ... Cited by 178 - Related articles - BL Direct - All 9 versions
- ►endojournals.org A Mari, WM Sallas, YL He, C Watson, M … - Journal of Clinical Endocrinology & Metabolism, 2005 - Endocrine Soc Results: Vildagliptin significantly increased the insulin secretory rate at 7
mmol/liter glucose (secretory tone), calculated from the dose response; the
difference in least squares mean ( LSM) was 101 ± 51 pmol·min –1 ·m ... Cited by 198 - Related articles - BL Direct - All 8 versions
B Ahrén, R Gomis, E Standl, D Mills, A … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—In patients randomized to LAF237, baseline HbA 1c averaged 7.7 ± 0.1%
and decreased at week 12 (Δ = −0.6 ± 0.1%), whereas HbA 1c did not change
from a baseline of 7.9 ± 0.1% in patients given placebo (between-group ... Cited by 313 - Related articles - BL Direct - All 8 versions
- ►endojournals.org B Ahren, M Landin-Olsson, PA Jansson, M … - Journal of Clinical Endocrinology & Metabolism, 2004 - Endocrine Soc The stimulation of insulin vs. inhibition of glucagon secretion in relation to
the antidiabetic action of glucagon-like peptide-1 (GLP-1) is not established.
Here, the influence of a 4-wk increase in circulating GLP-1 by inhibition ... Cited by 331 - Related articles - BL Direct - All 7 versions
S Ristic, S Byiers, J Foley, D Holmes - Diabetes Obesity and Metabolism, 2005 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 139 - Related articles - BL Direct - All 4 versions
D Holmes - Horm Metab Res, 2006 - rima.org The incretin hormones ± glucose−dependent insulinotropic poly− peptide
(GIP) and particularly glucagon−like peptide−1 (GLP−1) ± have been
reported to exert multiple metabolic effects that con− tribute to the ... Cited by 120 - Related articles - View as HTML - BL Direct - All 4 versions
- ►diabetesjournals.org E Bosi, RP Camisasca, C Collober, E … - Diabetes Care, 2007 - Am Diabetes Assoc RESULTS—The between-treatment difference (vildagliptin − placebo) in
adjusted mean change (AMΔ) ± SE in A1C from baseline to end point was −0.7
± 0.1% (P < 0.001) and −1.1 ± 0.1% (P < 0.001) in patients receiving 50 ... Cited by 150 - Related articles - BL Direct - All 10 versions
N Matikainen, S Mänttäri, A Schweizer, A … - Diabetologia, 2006 - Springer Abstract Aims/hypothesis We assessed the effects of vildagliptin, a novel
dipeptidyl peptidase IV inhibitor, on postprandial lipid and lipoprotein
metabolism in patients with type 2 diabetes. Subjects, materials and ... Cited by 64 - Related articles - BL Direct - All 5 versions
GA Herman, C Stevens, K Van Dyck, A … - Clinical Pharmacology & Therapeutics, 2005 - nature.com Background: Sitagliptin (MK-0431 [(2R)-4-oxo-4-(3-[trifluoromethyl]-5,6-dihydro[
1,2,4]triazolo[4,3-a]pyrazin-7[8H]-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine])
is an orally active, potent, and selective inhibitor of dipeptidyl ... Cited by 115 - Related articles - All 6 versions
AJ Garber, A Schweizer, MA Baron, E … - Diabetes, Obesity and Metabolism, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 113 - Related articles - All 5 versions
